Search results
Results From The WOW.Com Content Network
Modified-release dosage. Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [ 1]
Extended-release morphine. Extended-release (or slow-release) formulations of morphine are those whose effect last substantially longer than bare morphine, availing for, e.g., one administration per day. Conversion between extended-release and immediate-release (or "regular") morphine is easier than conversion to or from an equianalgesic dose ...
Guanfacine, sold under the brand name Tenex ( immediate-release) and Intuniv ( extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure. [ 3][ 9] Guanfacine is FDA-approved for monotherapy treatment of ADHD, [ 3] as well as being used for ...
Oxycodone, sold under various brand names such as Roxicodone, Endone, and OxyContin (which is the extended-release form), is a semi-synthetic opioid used medically for treatment of moderate to severe pain. It is highly addictive [14] and is a commonly abused drug.
Tamsulosin – ARISTO Pharma – 0.4 mg prolonged-release tablets – Urologikum. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones.
Based on Medicare and Medicaid spending between 2012 and 2017, prescriptions for extended-release drugs cost the healthcare system almost $14 billion more than would have been spent on equivalent ...
Methylphenidate. Methylphenidate, sold under the brand names Ritalin ( / ˈrɪtəlɪn / RIT-ə-lin) and Concerta ( / kənˈsɜːrtə / kən-SUR-tə) among others, is a potent central nervous system (CNS) stimulant used medically to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, narcolepsy. It is a primary ...
Viloxazine acts as a selectivenorepinephrine reuptake inhibitor(NRI). [6][1][5]The immediate-release form has an elimination half-lifeof 2.5 hours[6][2]while the half-life of the extended-release form is 7 hours. [1] Viloxazine was first described by 1972[10]and was marketed as an antidepressant in Europe in 1974.